ChemoCentryx, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 11.76 million compared to USD 1.81 million a year ago. Net loss was USD 31.65 million compared to USD 39.21 million a year ago. Basic loss per share from continuing operations was USD 0.44 compared to USD 0.56 a year ago.
For the six months, revenue was USD 17.22 million compared to USD 12.17 million a year ago. Net loss was USD 70.26 million compared to USD 68.92 million a year ago. Basic loss per share from continuing operations was USD 0.99 compared to USD 0.99 a year ago.